VivoSeq
Other

AIN

0

Pipeline Programs↗

39

Active Trials↗

38

Companies Involved↗

AIN is an early-stage landscape with 0 programs across 38 companies. The most active players are GSK, Novartis, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

41/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBiogen logo

Biogen

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

360

clinical trials

Completed230 · 64%
Unknown status37 · 10%
Terminated34 · 9%
Recruiting24 · 7%
Withdrawn17 · 5%
Not yet recruiting9 · 3%
Other9 · 3%

Clinical Trials

Trial Activity

360 trials

Luspatercept for Clonal Cytopenias of Uncertain Significance
Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT06788691·50 enrolled
From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects
Recruiting·MMassachusetts General Hospital·Phase 2·NCT05661903·180 enrolled
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Recruiting·BBeijing Pearl Biotechnology Limited Liability Company·Phase 3·NCT06930794·300 enrolled
Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: a Dimensional Approach
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 1·NCT03705715·200 enrolled
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Recruiting·AAxsome Therapeutics, Inc.·Phase 3·NCT06568367·520 enrolled
Brain Blood Vessel Responses to Changes in Blood Flow
Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT06629077·36 enrolled
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
Recruiting·UUniversity of Washington·Phase 2·NCT07088419·40 enrolled
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Recruiting·AAnnexon, Inc.·Phase 3·NCT07020819·30 enrolled
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06083883·44 enrolled
The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
Recruiting·—·N/A·NCT05067998·25 enrolled
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
Recruiting·—·Phase 2·NCT03728335·35 enrolled
Cocaine and Pentoxifylline (BED IN 47)
Recruiting·—·Phase 1·NCT07086794·30 enrolled
Dupilumab Effects Against Aeroallergen Challenge
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT05720325·88 enrolled
Tegoprazan-containing Sequential for H. Pylori
Recruiting·SSeoul National University Bundang Hospital·N/A·NCT06382493·400 enrolled
Whole Grain Job's Tear, Muscle Health, Blood Glucose and Lipid Level
Recruiting·TTaipei Veterans General Hospital, Taiwan·Phase 2·NCT06503172·80 enrolled
Page 1 of 24

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)